Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST
Paris (France), Cambridge (Massachusetts, USA), September 30 , 2020, 2.00 p.m.
CEST - BIOPHYTIS (Euronext Growth Paris) announces that the trading of its
shares (ISIN code : FR0012816825-ALBPS) and BSA (ISIN code :
FR0013507290-BPSBS) will resume on September, 2020 at 3.00 pm CEST.
Following the stock price suspension from trading asked on September 30 before
the stock exchange opening and the company's press release of this morning,
trading will resume on September 30, 2020 at 3.00 pm CEST.
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age-related diseases, including
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is
being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The
company plans to start the clinical development (MYODA) in H2 2020.
Sarconeos (BIO101) is also being developed as a treatment for patients with
COVID-19 related respiratory failure in a Phase 2/3 clinical study (COVA) in
the United States, Europe and Latin America.
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825). For more information visit www.biophytis.com
Biophytis Contact for Investor Relations Evelyne Nguyen, CFO